Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Head & Neck|September 18, 2008
Esthesioneuroblastoma: The Princess Margaret Hospital experienceGideon Bachar, David P Goldstein, Manish Shah, et al.
European Urology Focus|July 30, 2017
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone AcetateGiuseppe Di Lorenzo, Guru Sonpavde, Gregory Pond, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast CancerSusan Dent, Dean Fergusson, Olexiy Aseyev, et al.
Clinical Lung Cancer|February 21, 2017
A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, et al.
Breast Cancer Research and Treatment|March 19, 2014
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related eventsChristina L Addison, Nathaniel Bouganim, John Hilton, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast ReconstructionAngel Arnaout, Jing Zhang, Simon Frank, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancerEric K Nguyen, Hang Yu, Gregory Pond, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I StudyRena Buckstein, Graeme Fraser, Matthew Cheung, et al.
American Journal of Clinical Oncology|July 6, 2018
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal CancerAntonio Cubillo, Rafael Álvarez-Gallego, Manuel Muñoz, et al.
Pageof 9